Andreap Malizia News Today : Breaking News, Live Updates & Top Stories | Vimarsana

IAMA Therapeutics Announces First Subject Dosed in Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy

IAMA Therapeutics Announces First Subject Dosed in Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Andreap maliziaStefan klotterDravet syndromeGeorgia westDie performance strategieAssets sie

IAMA Therapeutics Announces Approval of Clinical Trial Application (CTA) by the Italian Medicines Agency (AIFA) to Initiate a Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy

IAMA Therapeutics Announces Approval of Clinical Trial Application (CTA) by the Italian Medicines Agency (AIFA) to Initiate a Phase 1 Study of IAMA-6 for the Treatment of Autism and Epilepsy
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Stefan klotterAndreap maliziaItalian medicines agencyClinical trial applicationChief executive officerGeorgia westLassen sie

IAMA Therapeutics to Present New Preclinical Data at Upcoming American Epilepsy Society 2023 Annual Meeting

IAMA Therapeutics to Present New Preclinical Data at Upcoming American Epilepsy Society 2023 Annual Meeting
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesAnnalisa savardiStefan klotterAndreap maliziaTeam leader neuropharmacologyAmerican epilepsy societyMesial temporal lobe epilepsyChief executive officerPoster presentationRefractory epilepsyGeorgia westLassen sie

IAMA Therapeutics to Present New Preclinical Data at Upcoming American Epilepsy Society 2023 Annual

Study results support the potential for IAMA-6 as a disease-modifying therapy for drug-resistant epilepsiesGENOA, Italy (BUSINESS WIRE) #autism IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain disorders, toda.

United statesAnnalisa savardiAndreap maliziaAmerican epilepsy societyTeam leader neuropharmacologyMesial temporal lobe epilepsyChief executive officerPoster presentationRefractory epilepsy

IAMA Therapeutics to Present at Sachs Associates 23rd Annual Biotech in Europe Forum

GENOA, Italy, September 13, 2023 IAMA Therapeutics, a pharmaceutical company focused on the discovery, development, and commercialization of novel medicines for children affected by brain disorders, today announced that Andrea P. Malizia, Ph.D., Chief Executive Officer, will present and participate in the "Advances in Approaches to Neurological Disorder" panel at the Sachs Associates 23rd Annual Biotech in Europe Forum, taking place September 20-21, 2023, in Basel, Switzerland.

Andreap maliziaBiotech in europe forumSachs associatesCompany presentationPanel discussionChief executive officerAnnual biotechEurope forumCompany presentationPharmaceutical companySachs associatesBusiness wireBrain disorders